The dual hit hypothesis of schizophrenia: evidence from animal models
Glenmark Pharmaceuticals List of Tables Table 1 List of secondary sources Table 2 List of abbreviations Table 3 Global GLP-1 receptor agonist market, by region, 2021-2033 (USD Million) Table 4 Global GLP-1 receptor agonist market, by product, 2021-2033 (USD Million) Table 5 Global GLP-1 receptor agonist market, by application, 2021-2033 (USD Million) Table 6 Global GLP-1 receptor agonist market, by route of administration, 2021-2033 (USD Million) Table 7 Global GLP-1 receptor agonist market, by distribution channel, 2021-2033 (USD Million) Table 8 North America GLP-1 receptor agonist market, by country, 2021-2033 (USD Million) Table 9 North America GLP-1 receptor agonist market, by product, 2021-2033 (USD Million) Table 10 North America GLP-1 receptor agonist market, by application, 2021-2033 (USD Million) Table 11 North America GLP-1 receptor agonist market, by route of administration, 2021-2033 (USD Million) Table 12 North America GLP-1 receptor agonist market, by distribution channel, 2021-2033 (USD Million) Table 13 U.S
Longer treatment duration
Saxenda (liraglutide) : Earlier-generation GLP-1 medication showing approximately 8% weight loss over 56 weeks in clinical trials
1a), independently of the capping agent, composition and experimental conditions
H.HuangS
